Vavricka John 4
4 · Atea Pharmaceuticals, Inc. · Filed Feb 2, 2024
Insider Transaction Report
Form 4
Vavricka John
Chief Commercial Officer
Transactions
- Sale
Common Stock
2024-02-01$3.84/sh−11,819$45,420→ 21,515 total - Exercise/Conversion
Restricted Stock Units
2024-01-31−33,334→ 66,666 total→ Common Stock (33,334 underlying) - Exercise/Conversion
Common Stock
2024-01-31+33,334→ 33,334 total - Award
Stock Option (Right to Buy)
2024-01-31+132,800→ 132,800 totalExercise: $4.16Exp: 2034-01-30→ Common Stock (132,800 underlying)
Holdings
- 82,508(indirect: By Trust)
Common Stock
Footnotes (4)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- [F2]Shares were sold solely to cover taxes upon the vesting of restricted stock units pursuant to a standing Rule 10b5-1 instruction dated March 25, 2022.
- [F3]The original grant of 100,000 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026.
- [F4]The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2024 such that the option is fully vested on January 31, 2028.